Bigger Bioreactors Won’t Solve Every AAV Manufacturing Challenge

The AAV field has spent years tackling one problem: how to manufacture effective gene therapies.

Now, an equally important question is emerging: How do we make enough of it?

As AAV-based therapies move from ultra-rare and rare diseases toward broader clinical use, manufacturing is becoming an increasingly important factor determining success. The challenge is not simply increasing production volume, but rather building processes that can produce products with the right efficiency, at the right cost, with the reliability required at scale.

It completely changes the way we think about AAV manufacturing.

The next generation of AAV manufacturing may not come from simply building larger facilities with more personnel or adding more purification capacity. Some of the most meaningful gains may come much earlier in the production process, by improving what happens inside the bioreactor.

Scale is not just a bigger bioreactor

When we talk about scaling AAV production, it is tempting to think primarily in terms of volume. You scale a 200 L process by 10-fold into a 2,000 L bioreactor and expect a 10-fold increase in vector production, right?

But scale-up is rarely that simple.

AAV production, at its core, is a biological process. Cells respond to their environment, and small changes in cell culture, nutrient availability, cell density, and perhaps most importantly, transfection conditions, can influence both yield and quality of the final titer.

As a result, scaling AAV production is not simply a matter of making the same process larger. The conditions that work on a benchtop shake flask do not always directly translate to a bioreactor. This is particularly important for AAV production, where transfection plays a critical role. As the process scales, maintaining efficient and consistent transfection becomes increasingly critical.

Transfection Is a Key Driver of Process Performance

At the heart of AAV production is a key step that determines both yield and consistency of the final product: transfection. Efficiency and reproducibility in transfection can have lasting effects on upstream productivity and downstream clarification and purification.

But efficiency alone is not enough. When the culture scale is increased from mL to L and beyond, variables like transfection complex volume, stability, mixing, etc. become increasingly important. Larger scales introduce new demands, so a truly scalable manufacturing process needs performance that can be maintained as process conditions change. Additionally, the performance needs to remain consistent from lot-to-lot and operator-to-operator.

Transfection is also a major cost driver in transient AAV production. GMP-grade plasmid DNA can be extremely expensive, particularly at large scale, and increasing culture volume increases the amount of plasmid and transfection reagent required. Improving transfection efficiency while minimizing the amount of DNA required can reduce the amount of raw material required, thus significantly reducing the overall cost per dose.

The opportunity ahead

The answer to increasing AAV manufacturing capacity is not simply building bigger bioreactors. If transfection efficiency changes as the process scales, simply increasing the size of the bioreactor does not solve the underlying problem.

Improving transfection performance during process development can have a much larger impact. Higher efficiency, lower plasmid requirements, and stable complexes can improve productivity while reducing one of the major costs associated with transient AAV production.

As AAV manufacturing continues to scale, these improvements will become increasingly important. The focus should not just be on how much material a bioreactor can produce, but on how efficiently and consistently it can produce it.

Aav manufacturing, Cell and gene therapies, Upstream